与temozolomide管理相关的药物不良事件:使用FAERS数据库从2014年到2024年的真实世界药监测研究
Wenpei Chen1, Deji Wu1, Xianjun Chen1
1Department of Neurosurgery, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China.
概括
这项研究系统地确定了与常见的质母细胞瘤治疗方法temozolomide相关的不良事件 (AE). 这些发现突出了潜在的风险,并为这种重要的化疗药物的更安全的临床使用提供了信息.
科学领域:
- 在瘤学瘤学.
- 药物监督 药物监督 药物监督
- 临床药理学 临床药理学
背景情况:
- 泰莫索洛米德是多形质母细胞瘤 (GBM) 和形星细胞瘤的关键化剂.
- 越来越多的temozolomide使用需要对其不良事件 (AE) 进行系统的记录.
- 药物监测对于评估药物的益处和风险至关重要.
研究的目的:
- 使用现实世界的数据,系统地识别与temozolomide相关的AE.
- 分析来自FDA不良事件报告系统 (FAERS) 的AE信号.
主要方法:
- 分析了来自FDA不良事件报告系统 (FAERS) 的11,400份报告.
- 识别AE信号及其相关的系统器官类 (SOC).
- 鉴定的副作用与现有药物标签的比较.
主要成果:
- 在27个SOC中确定了200个AE信号,在血液/淋巴系统 (ROR=6.32) 和一般疾病中发现了显著的发现.
- 检测到新的可疑AE,包括变种效应,阿斯伯吉洛症和内出血.
- 大多数副作用发生在temozolomide治疗的第一个月内.
结论:
- 这种系统分析提供了对temozolomide真实世界的安全性概况的关键见解.
- 这些发现可以指导优化temozolomide治疗方案.
- 对AEs的更好理解将改善患者的安全性和治疗结果.
相关概念视频
Pharmacovigilance
1.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.0K
Drug Administration and Therapy Phases: Overview
779
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
779
Teratogenicity
2.8K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.8K
Drug Regulation
1.9K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.9K
Hazard Ratio
261
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
261
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
330
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
330


